Horizon Discovery, one of theglobal leaders in the application of gene editing and gene modulation technologies, announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizons next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patients cells either directly in the body (gene therapy), or externally before transplanting back into the patient (cell therapy). This platform will also expand the companys research tools and service provisions.
The company formed an exclusive partnership with Rutgers in January 2019 to further develop the novel base editing technology invented by Dr. Shengkan Jin, associate professor of pharmacology, and co-inventor Dr. Juan C. Collantes, post-doctoral research fellow at Rutgers Robert Wood Johnson Medical School, and has since been funding research in base editing at the University while undertaking its own evaluation and proof-of-concept studies. Horizon has a number of internal programs designed to accelerate the clinical uptake of this technology and is now seeking 35 partners to assess and shape the development of its Pin-point base editing platform.
Horizon will offer partners access to a novel system that could be used to progress more effective multi-gene knockout cell therapy programs through clinical development with an improved safety profile. Partners will also gain access to the companys expertise in genome engineering of different cell types, access to early technical data, and influence over the direction of future development.
Base editing is a novel technology for engineering DNA in cells, which the potential to correct certain errors or mutations in the DNA, or inactivate disease-causing genes. Compared with currently available gene editing methodologies such as conventional CRISPR/Cas9, which creates cuts in the gene that can lead to adverse or negative effects, this new technology allows for accurate gene editing while reducing unintended genomic changes that could lead to deleterious effects in patients.
Dr. Jonathan Frampton, Corporate Development Partner, Horizon Discovery, said: The technology could have a significant impact in enabling cell therapies to be progressed through clinical trials and towards commercialization. Horizon is pleased to offer an effective and precise base editing technology and, alongside Rutgers, aims to make base editing available to all appropriate cell and gene therapy companies as well as research departments. Partnering with leading organizations will help us to drive innovation and deliver the best therapy for the patient.
Dr. Shengkan 'Victor' Jin of Rutgers University stated: The cytidine deaminase version of the technology alone could potentially be used for developing cell therapies such as gene modified cells for sickle cell anemia and beta thalassemia, HIV resistant cells for AIDS, over-the-shelf CAR-T cells for cancer, and MHC-compatible allogenic stem cells for transplantation. Other applications could include use as gene therapies for inherited genetic diseases including antitrypsin deficiency and Duchenne muscular dystrophy. In addition, we intend to take full advantage of the unique modularity and versatility features of Pin-point platform and develop efficient gene inactivation agents for potential treatment of many devastating diseases where the leading causal contributing factors are well defined. At the top of this disease list are Alzheimers disease, amyotrophic lateral sclerosis, and familial hypercholesterinemia.
Dr. S. David Kimball, Senior Vice President for Research and Economic Development at Rutgers University, added: The gene editing technology developed by Rutgers has the potential to revolutionize how scientists think about their search for better options and outcomes in the treatment of disease. It has the potential to solve some of the most persistent global health challenges. This partnership with Horizon Discovery is paving the way to deliver biotherapies for precision medicine and diagnostics and improve human health. I am proud that Rutgers, together with Horizon, is among the frontrunners in the field of gene editing.
Want more of the latest science news straight to you inbox? Become a SelectScience member for free today>>
See more here:
Horizon to provide access to novel base editing technology - SelectScience
- Latest Insights on Stem Cell Assay Market Business Strategies, Acquisitions, Revenue Analysis Share, Forecast to 2028 | by Perkinelmer Inc, Promega... - October 13th, 2022
- S.I. school hosts dance-a-thon to support 9-year-old student with sickle cell disease - SILive.com - October 13th, 2022
- Cord blood bank - Wikipedia - October 4th, 2022
- Cell Reprogramming Market is Expected to Record the Massive Growth, with Prominent Key Players Allele Biotechnology, ALSTEM, Applied Biological... - September 16th, 2022
- Pleco Therapeutics Announces Final Close of its Series A Financing Raising 17.3m to Progress its Novel Plecoid Product in Acute Myeloid Leukaemia to... - September 8th, 2022
- Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - KULR-TV - August 14th, 2022
- Cell Expansion Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 Shanghaiist - Shanghaiist - August 5th, 2022
- 3D Bioprinting for Tissue and Organ Regeneration Market worth $424.3 Million by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance - July 27th, 2022
- After conquering sickle cell and multiple sclerosis, it was COVID-19 that claimed her - Lynchburg News and Advance - July 11th, 2022
- Stem Cell Therapy Market to Observe Exponential Growth By 2022 to 2030 | Smith, Nephew (UK), MEDIPOST Co Ltd. (South Korea) - Digital Journal - June 22nd, 2022
- Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with... - June 22nd, 2022
- This Key Protein Is Essential for Brain Cell Longevity and Growth - SciTechDaily - June 13th, 2022
- Stem Cell Cartilage Regeneration Market to Witness Massive Growth from 2022 to 2030 | Central members covered as a piece of this study incorporate... - June 13th, 2022
- Stem Cell Therapy Market Size, Scope and Forecast | Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd.,... - June 4th, 2022
- Advanced Therapy Medicinal Products (ATMP) Service Providers Market worth $34.59 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo... - June 4th, 2022
- Gene Therapy Market Size, Scope and Forecast | Novartis AG, Biogen, Gilead Sciences MolMed SpA, Spark Therapeutics Orchard Therapeutics plc., SIBIONO,... - June 4th, 2022
- Cell Isolation/Cell Separation Market Size, Scope and Forecast | Beckman Coulter (Subsidiary of Danaher Corporation), Becton, Dickinson and Company,... - June 4th, 2022
- 8 Players Leading the 3D Printed Meat Revolution - 3DPrint.com - May 2nd, 2022
- Penn researchers discover new cell type in human lung with regenerative properties - EurekAlert - April 6th, 2022
- FDA Grants Fast Track Designation to CYNK-001 for AML Treatment - Targeted Oncology - January 5th, 2022
- Stem Cell Therapy: a Look at Current Research, Regulations ... - December 24th, 2021
- Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia - LSMedia - December 24th, 2021
- Peaceful Protest at Cherry Hill Women's Center Warning Public of Increase in Late Term Abortions In New Jersey. - InsiderNJ - October 16th, 2021
- Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper - August 18th, 2021
- Avalon GloboCare, UPMC Hillman and University of Pittsburgh to develop new cancer immunotherapy - Proactive Investors USA & Canada - August 5th, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 21st, 2021
- ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment - PRNewswire - July 21st, 2021
- GXGX Merger: The SPAC News That Has GXGX Stock Soaring - InvestorPlace - July 21st, 2021
- This Startup is Changing the Way Spinal Cord Injury Is Treated Around the World - Entrepreneur - June 23rd, 2021
- Genmab Announces that Janssen has Received European - GlobeNewswire - June 23rd, 2021
- Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom - May 13th, 2021
- Commencement stories from Rowan paint a picture of opportunities near and far - NJ.com - May 13th, 2021
- Vitalant to Hold Blood Donation Event on December 5 in Freehold - TAPinto.net - December 1st, 2020
- Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire - October 23rd, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 23rd, 2020
- Novel Strategies for Targeting the Guardian of the Genome Emerge - OncLive - October 23rd, 2020
- CRISPR Market to See Massive Growth by 2026 | GE Healthcare Dharmacon, CRISPR Therapeutics, Thermo Fisher Scientific - Aerospace Journal - October 23rd, 2020
- Smith's 2005 stem cell law to be reauthorized by House - InsiderNJ - October 4th, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- 99-million-year-old fight between hell ant and its prey preserved in amber - BBC Focus Magazine - August 12th, 2020
- Vitalant to Hold Blood Donation Drive on August 11 in Atlantic Highlands - TAPinto.net - August 12th, 2020
- Stem Cells Sales Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Mesenchymal Stem Cells Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2019 Break Down by Top Companies, Countries, Applications, Challenges,... - June 10th, 2020
- Stem Cells Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty - June 10th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with... - June 10th, 2020
- CO2 Incubators Market is Expected to Witness a Steady Growth by 2025 - Farmers Ledger - June 4th, 2020
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... - May 13th, 2020
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... - May 6th, 2020
- CO2 Incubators Market Update: Uncover the Business Strategies of Leaders & Laggards of the Market - 3rd Watch News - March 6th, 2020
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today - March 4th, 2020
- Are stem cells really the key to making humans live longer? - Wired.co.uk - February 16th, 2020
- Musicians and community coming together in Asbury Park to help Point Pleasant 3-year old - Asbury Park Press - February 12th, 2020
- TV Guy: A return to history with Auschwitz Untold - New Jersey Herald - January 27th, 2020
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 - January 20th, 2020
- Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance - January 15th, 2020
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise - January 15th, 2020
- Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll - January 15th, 2020
- Stemming the Tide Confronting Anti-Semitism in the 21st Century - The Times of Israel - January 5th, 2020
- Weekly pick of Neuroscience news from around the world - Brain Tumour Research - November 30th, 2019
- Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald - November 28th, 2019
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... - November 6th, 2019
- Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury - November 6th, 2019
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Live Cell Imaging Consumables Market Evolving to a Next-Generation Strategy with New Partnerships, Technologies and Targets by 2023 key players LCC... - November 6th, 2019
- Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury - November 6th, 2019
- PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury - November 6th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly - November 2nd, 2019
- Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly - November 2nd, 2019
- Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - November 2nd, 2019
- On Stage: Allegaeon ready to rock Philly - The Unionville Times - November 2nd, 2019
- Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly - October 14th, 2019
- Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly - October 14th, 2019
- PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly - October 14th, 2019
- Obtain Stem Cell Therapy in New Jersey - Stem Cell Miami - February 23rd, 2019